Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

132.73
-5.2000-3.77%
Post-market: 132.800.0700+0.05%19:48 EDT
Volume:337.36K
Turnover:45.43M
Market Cap:1.91B
PE:-27.10
High:139.23
Open:135.57
Low:131.65
Close:137.93
52wk High:161.38
52wk Low:60.49
Shares:14.41M
Float Shares:8.40M
Volume Ratio:1.62
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:8.82
PE(LYR):-35.80

Loading ...

Palvella Therapeutics COO Kathleen Goin Disposes of 4,302 Common Shares Worth $642,194.57

Reuters
·
Jul 18

Palvella Therapeutics Highlights Growth Plans and QTORIN Progress

TIPRANKS
·
Jul 15

Palvella Therapeutics Director Matthew Pauls Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Jul 01

Palvella Therapeutics Adds Industry Veteran to Board

TIPRANKS
·
Jun 30

Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors

Reuters
·
Jun 30

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.d., M.b.a., to Board of Directors

THOMSON REUTERS
·
Jun 30

Palvella submits first rolling new drug application to FDA for Qtorin

TIPRANKS
·
Jun 29

Palvella Submits First NDA Module to FDA for Qtorin Rapamycin Under Rolling Review

Reuters
·
Jun 29

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for Qtorin™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

THOMSON REUTERS
·
Jun 29

Palvella Therapeutics - Expects to Complete Nda Submission in H2 2026

THOMSON REUTERS
·
Jun 29

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)

TIPRANKS
·
Jun 24

Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71

Reuters
·
Jun 23

Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)

TIPRANKS
·
Jun 22

Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 22

FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin

TIPRANKS
·
Jun 22

FDA grants rolling review for Palvella QTORIN rapamycin NDA in microcystic lymphatic malformations

Reuters
·
Jun 22

FDA Grants Rolling Review of Palvella’s Qtorin™ Rapamycin Nda for Microcystic Lymphatic Malformations

THOMSON REUTERS
·
Jun 22

Palvella Therapeutics - to Complete Qtorin Rapamycin Nda Submission in Second Half of 2026

THOMSON REUTERS
·
Jun 22

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

TIPRANKS
·
Jun 14